Andson Biotech

Andson Biotech, located in Atlanta, Georgia, operates within the healthcare industry, specifically focusing on the development and manufacturing of advanced cell-based therapies. The company, which has a team size of two, was selected into prestigious accelerators such as the 2023 BioTools Innovator Accelerator and the inaugural Merck Digital Sciences Studio. Backed by Y Combinator in the W22 batch, Andson Biotech aims to revolutionize therapies in areas like biologics, cell and gene therapies, tissue engineered medical products, and modern vaccine technologies. Their mission emphasizes accelerating the discovery, development, and manufacturing processes to make these therapies widely accessible and affordable. Andson Biotech has developed the DynaCHIP technology, which facilitates rapid intracellular mass spectrometry from small numbers of cells, and is also working on enhancing biomanufacturing tools to improve outcomes using in-line biomarker monitoring. The company collaborates with partners such as In Vivo T-Cells, IPSC Derived T-Cells, and Advanced Tissue Manufacturing, and has garnered support from notable investors in the biotech and healthcare sectors.